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An increase in biological ageing is now commonly 
recognized in chronic diseases such as chronic kidney 
disease and chronic obstructive pulmonary disease [1, 2]. 
In this issue, Vujkovac et al. [3] present data suggesting 
that Fabry disease may be a disease associated with pre-
mature ageing. The authors assessed telomere length 
(TL) and telomerase activity in a cohort of 33 patients 
with Fabry disease. Whereas in male patients, the authors 
observed a reduced TL as compared to age-matched con-
trols, females presented with a higher telomerase activity 
without a significant difference in TL. The authors did 
not observe a difference in TL or telomerase between pa-
tients with or without enzyme replacement therapy 
(ERT), nor did they observe a relationship between TL 
and renal function. Telomere attrition is a feature of 
ESRD associated with persistent inflammation that pre-
dicts poor outcome [4].
Fabry disease is associated with a significantly reduced 
life expectancy compared to the general population [5], 
and therefore, the association with a premature ageing 
process is not unexpected. However, establishing biolog-
ical age is not straightforward. Both phenotypical criteria 
and biomarkers are used for this purpose. Whereas phe-
notypically premature ageing is characterized by frailty, 
sarcopenia, reduced physical function, and cognitive dys-
function; these are not definite criteria for its diagnosis 
[6]. Whereas a reduced executive function and informa-
tion processing speed were observed in patients with Fab-
ry disease, and global cognition appeared to be preserved 
[7]. We could not identify studies from the literature as-
sessing frailty, body composition, or physical function in 
adults with Fabry disease. 
Regarding ageing biomarkers, telomere attrition, 
which was measured in this study, has been associated 
with outcomes at a population level in different disease 
states, but is generally considered to be an insensitive bio-
marker [8]. The ageing process is typified by significant 
interindividual variation and differences in physiological 
function between individuals of the same chronological 
age. This holds also for TL. The case for TL as a biomark-
er of ageing has been made repeatedly [9]. Systematic re-
views of the evidence relating TL to outcome have found 
few actual mortality studies, all of which suffered from 
survivor bias. Few studies have examined the relationship 
with age-related decline in physiological function. Data 
from these were equivocal and all lacked statistical power 
[10, 11]. TL as a biomarker of age-related health is beset 
by methodological issues and has proven inferior to the 
use of CDKN2A [12, 13].
An exciting alternative has been the use of methyla-
tion-based epigenetic clocks, which show good correla-
tions with chronological age and acceleration in disease 
states [14]. Caveats to their use, however, include their 
degree of fit with physiological function in normative 
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ageing, a limited understanding of the significance of 
their respective methylation sites and the underlying 
mechanism. Additionally, the associated methylation 
sites lack conservation between species.
More recently, a ribosomal DNA-based clock has been 
described [15], with a proposed mechanism based on 
DNA methylation counteracting increased nucleolar size 
and rDNA transcription levels. This is also consistent 
with the MTR (mitochondrial, telomere nucleo-protein 
complexes, and control of ribosome synthesis) theory of 
ageing, as described in [16].
At a molecular and cellular level, 9 hallmarks are as-
sociated with the ageing process, namely, genomic insta-
bility, telomere attrition, altered intracellular communi-
cation (such as due to inflammation), epigenetic altera-
tions, loss of proteostasis, deregulated nutrient sensing, 
mitochondrial dysfunction, cellular senescence, and stem 
cell exhaustion [17] (Fig. 1).
In patients with Fabry disease or in experimental mod-
els, dysregulation of several of these hallmarks has been 
identified. Whereas telomere attrition was observed in 
the study of Vujkovac et al. [3] and Squillaro et al. [18] 
observed DNA damage in a mesenchymal stem cell line 
despite the activation of DNA damage. 
Regarding altered intracellular commination, Fabry 
disease is characterized by chronic low-grade systemic 
inflammation [19], resulting from an interaction be-
tween Gb3 and toll-like receptors, which likely contrib-
utes to tissue damage [20]. In the study of Vujkovac et al. 
[3], no relation between levels of proinflammatory bio-
markers and TL was observed. However, given the small 
sample size, this does not necessarily suggest that sys-
temic inflammation is not involved in the ageing process 
given the cross-sectional nature of the study. With re-
spect to loss of proteostasis, dysregulated autophagy, 
which serves for the removal of cellular waste products, 
has been identified in cellular cultures with α-Gal A de-
pletion [21]. Furthermore, nutrient sensing did seem to 
be in a podocyte cell culture model in Fabry disease, giv-
en the lower expression of mechanistic target of rapamy-
cin. Nutrient sensing in the ageing process is a compli-
cated phenomenon. Whereas activation of the anabolic 
pathways such as mechanistic target of rapamycin leads 
to accelerated ageing in experimental models, a down-
regulation of this pathway can be a defense mechanism 
under cell stress, preserving energy for cellular survival 
[17, 22].
With respect to mitochondrial dysfunction, a recent 
study has shown higher plasma markers reflecting 
 oxidative stress in patients with Fabry disease on ERT 
[23], which is possibly in part related to superoxide dis-
mutase 2 downregulation [24]. Squillaro et al. [18] 
showed that α-Gal A deficiency induced cell cycle arrest 
and senescence in cultures of amniotic and bone- 
marrow derived mesenchymal stem cells. In conclu-
sion, there are several arguments for a disturbance in 
the “hallmarks” of ageing in patients and models of 
Fabry disease, although definitely more research is 
needed. 
ERT did not appear to affect telomere attrition. 
 Indeed, it has been shown that ERT can delay disease 
manifestation, and it is not able to completely prevent 
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Fig. 1. Hallmarks of aging. From [17], with 
permission.
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the progression of organ damage in Fabry disease [25]. 
Inflammatory markers were even higher on patients re-
ceiving ERT, which might be a consequence of 
 confounding by indication. An important characteristic 
of α-Gal A-depleted cell lines is an impairment of 
 autophagy and protein turnover, leading to an increase 
in oxidative stress, which does not seem to be fully re-
versible by ERT [21, 23, 26]. The role of defective au-
tophagy in the ageing process is increasingly recognized 
[27]. 
In a recent study, ERT cleared Gb3 from podocytes in 
cell cultures but was not able to normalize dysregulated 
autophagy, TGF-β expression, or oxidative stress, sug-
gesting that other as yet incompletely identified mecha-
nisms beyond Gb3 accumulation also are involved in the 
organ damage of FD [21, 23]. Also, ERT did not appear 
to be able to normalize the decreased energy metabolism 
in pluripotent stem cell-derived cardiomyocytes that 
were reprogrammed with a mutated GLA gene of a pa-
tient with Fabry disease [28]. 
Despite existing controversy around this subject 
[29], it has been suggested that skewing of X chromo-
some inactivation affects the phenotype of female 
 patients with FD [29]. Whereas patients with random 
inactivation showed a progressive course with advanc-
ing age, Echevarria et al. [30] have observed that those 
with skewed inactivation displayed either a mild course 
or a rapidly progressive course of the disease depending 
on the expression of the mutant GLA allele. Ageing has 
been shown to induce skewing of lead X chromosome 
expression, which has been implicated in the pathogen-
esis of several auto-immune disorders [31]. It might be 
hypothesized that biological ageing, by inducing 
 skewing of X chromosome inactivation, may also play 
a role in the progression of FD and its phenotypic ex-
pression in females in a mutually reinforcing way. 
However, this assumption needs to be addressed in fu-
ture studies.
The finding that females, who usually have a milder 
form of disease, had telomere levels comparable to con-
trols, but higher telomerase levels are intriguing. It was 
suggested that a higher telomerase level serves as a tem-
porary compensatory mechanism under stressful condi-
tions in order to preserve TL, whereas data from dialysis 
patients showing both reduced TL and telomerase activ-
ity suggest that this process is exhausted with more pro-
gressive disease [32]. This assumption is also supported 
by the fact that telomerase was decreased in male patients 
with eGFR levels < 60 mL/min/1.73 m2. Interestingly, 
whereas it might be logically argued that a decrease in re-
nal function would be primarily responsible for the telo-
mere attrition in FD patients given the fact that chronic 
kidney disease is considered a model of premature ageing 
[2, 4], TL was not related to an impairment in renal func-
tion, nor to cardiac biomarkers. In future studies, it would 
be interesting to study the relation between more specific 
aging biomarkers and specific organ dysfunction in more 
detail. 
The findings of Vujkovac et al. [3] are intriguing and 
stimulate larger studies to assess the relation between 
aging biomarkers, markers of metabolic load such as 
Gb3, as well as detailed phenotypical alterations. 
Whether the present results have therapeutic implica-
tions is yet uncertain. Generalized strategies to delay 
premature aging include generic factors, such as exer-
cise [33], whereas at the horizon, senolytic drugs, such 
as quercetin, fisetin, and dasatinab, are emerging as po-
tential treatments for conditions associated with pre-
mature ageing [34]. Another promising target appears 
to be the transcription factor NRF2-KEAP1 and in-
creased oxidative stress [35], which may be involved in 
both specific organ damage as well as a generalized ag-
ing process [36].
At present, the study of Vujkovac et al. [3] presents 
preliminary evidence that Fabry disease may represent 
another model of premature aging. Future research could 
shed more light on the systemic nature of the disease, 
which possibly extends even beyond the multiorgan in-
volvement directly related to G3b accumulation. This 
study should be followed by larger and more detailed 
studies looking into mechanisms and potential targets to 
prevent premature ageing in Fabry disease beyond the 
conventional treatment strategies. 
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